[文献资料]参 考 文 献

Phase Ⅲ study of first-line XELOX plus bevacizumab（BEV）for 6 cycles followed by XELOX plus BEV or single-agent（s/a）BEV as maintenance therapy in patients（pts）with metastatic colorectal cancer（mCRC）：The MACRO Trial（Spanish Cooperative Group for the Treatme ......